1-2 of 2
Ralf Naumann, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD
Journal: Blood
Blood (2007) 110 (11): 4825.
https://doi.org/10.1182/blood.V110.11.4825.4825
Published: 2007
Journal Articles

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).

Manfred Hensel, MD, Lars Scheuer, MD, Hans Salwender, MD, Juergen Finke, MD, Dieter Buerkle, MD, Heinz Albert Duerk, MD, Andreas Kaebisch, MD, Ralf Naumann, MD, Hans-Juergen Staiger, MD, Ingo Schmidt-Wolf, MD, Martin Kornacker, MD, Eugen Leo, MD, Joseph Fischer, MD, Anthony D. Ho, MD
Journal: Blood
Blood (2004) 104 (11): 4584.
https://doi.org/10.1182/blood.V104.11.4584.4584
Published: 2004